VolitionRx Achieves 99% Pure Cancer DNA Isolation in Liquid Biopsy Breakthrough
Event summary
- VolitionRx isolated >99% pure circulating tumor-derived DNA (ctDNA) using a novel two-step method.
- The company submitted an updated manuscript detailing the breakthrough on March 18, 2026.
- VolitionRx claims this is a world-first in liquid biopsy technology, with potential applications in early cancer detection and minimal residual disease (MRD) monitoring.
- The company is in active discussions with global diagnostic leaders to accelerate commercialization.
- The technology targets a $36 billion total addressable market (TAM) in early cancer detection and MRD.
The big picture
VolitionRx's breakthrough in isolating pure cancer DNA addresses a significant challenge in liquid biopsy technology, where the majority of circulating DNA comes from healthy cells. This advancement positions the company at the forefront of early cancer detection and MRD monitoring, sectors poised for substantial growth as precision medicine gains traction. The technology's potential to capture a subset of virtually pure ctDNA could redefine diagnostic standards, provided it passes rigorous clinical validation.
What we're watching
- Commercialization Pace
- The speed at which VolitionRx can secure licensing and distribution agreements with diagnostic leaders will determine the technology's market penetration.
- Validation Success
- The outcome of further validation cohorts, particularly for early-stage cancers, will be critical in assessing the technology's clinical utility.
- Market Adoption
- The extent to which the technology can be integrated with existing diagnostic tools, such as Volition's Nu.Q® assay, will influence its adoption in the healthcare sector.
Related topics